The London Life Sciences team advised Quanta Dialysis Technologies on its completion of a $245 million oversubscribed Series D funding round, the largest private funding round for a dialysis device company in history.
The financing round was led by Glenview Capital and co-led by Novo Holdings, with support from a broad group of other top-tier investors, including BlackRock, Eldridge, Sands Capital, Millennium Management, Monashee Investment Management LLC., Puhua Capital, Segulah Medical and Ancora. Existing shareholders also participated in the round, including Wellington Partners, btov, Seroba Life Sciences and The Grands.
Quanta Dialysis Technologies is an international commercial-stage, technology-enabled dialysis innovator intended to improve dialysis experiences and help people live more freely.
The funding announced today will allow Quanta to scale up global operations with a focus on the United States, where SC+ received 510(k) clearance from the FDA in December for use in acute and chronic care facilities. The company is investing in significant infrastructure to scale up manufacturing, sales and customer service functions to support use in currently approved care settings within the United States, while also preparing to launch a study to support its future FDA clearance for in-home use within the United States.
For additional details on the funding round, read the press release.